Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Optinose, Inc.
Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
August 08, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
August 02, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Expanded Access to XHANCE with Addition to National Commercial Formularies
June 27, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 17, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
May 14, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
May 10, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Announces $55 Million Registered Direct Offering
May 09, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
April 25, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose to Present at the Needham Virtual Healthcare Conference
April 04, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
March 15, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
March 07, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
February 29, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
January 18, 2024
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
December 06, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
November 22, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
November 09, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
October 27, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose to Present at the 2023 Cantor Global Healthcare Conference
September 22, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
August 10, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
July 27, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose to Present at the Jefferies Healthcare Conference
June 02, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
May 11, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
May 04, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Announces Reporting Date for First Quarter 2023 Financial Results
May 01, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 18, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose to Present at the Needham Virtual Healthcare Conference
April 12, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
March 07, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
February 28, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
February 21, 2023
From
Optinose, Inc.
Via
GlobeNewswire
Tickers
OPTN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.